medigraphic.com

2009, Número 5

Siguiente >>

Cir Cir 2009; 77 (5)


Estatinas en influenza. Momento de un estudio clínico controlado

Carrillo-Esper R

Idioma: Español
Referencias bibliográficas: 24
Paginas: 351-352
Archivo PDF: 62.57 Kb.


FRAGMENTO

Nuestro país experimentó el impacto de una epidemia de influenza. Este brote por la cepa H1N1 afectó a gran número de compatriotas y condicionó pánico, inestabilidad económica e incremento en los costos de salud del gobierno federal y de las instituciones públicas y privadas. Los brotes de influenza son periódicos, pueden o no ser estacionales y la gravedad de la enfermedad está relacionada a la inmunidad del huésped y a la cepa del virus. De presentarse una pandemia como la de 1918, se calcula que aproximadamente 175 a 350 millones de seres humanos pudieran morir y los sistemas de salud enfrentarían una situación catastrófica, ya que serían insuficientes los antivirales, las vacunas y la infraestructura hospitalaria. Por este motivo, deben desarrollarse nuevas alternativas terapéuticas que tengan como objetivo contener la enfermedad transmisible, y que además sean costo-efectivas y accesibles a toda la población.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lipatov AS, Govorkova EA, Webby RJ. Influenza: emergence and control. J Virol 2004;78:8951-8959.

  2. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med 2002;76:105-115.

  3. Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden FG. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol 2001;64:262-268.

  4. Lipatov AS, Andreansky S, Webby RJ. Pathogenesis of Hong-Kong H5N1 influenza virus NS gene reassortants in mice: the role of cytokines and B and T cell responses. J Gen Virol 2005;86:1121-1130.

  5. Nimmerjahn L, Dudziak D, Dirmeier U. Active NF-kB signalling is a prerequisite for influenza virus infection. J Gen Virol 2004;85:2347-2356.

  6. Beigel H, Farrar H, Han AM, Haiden FG, Hyer R, De Jong MD, et al. Avian influenza A (H5N1) infections in humans. N Engl J Med 2005;353:1373-1385.

  7. Ho Y, Wang JL, Wang JT, Wu UI, Chang CW, Wu HS, et al. Prognostic factors for fatal Adult influenza pneumonia. J Infect. 2009. Available at: http://www.journalofinfection.com/article/abstracts?terms1=Prognostic+factors+for+fatal+adult&terms2=&terms3=&terms4=

  8. Schonbeck U, Libby P. Inflammation, immunity and HMG-CoA reductaseinhibitors: statins as anti-inflammatory agents? Circulation 2004;109:18-26.

  9. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-987.

  10. Merx MW, Liehn EA, Graf J, De Sandt A, Schaltenbrand M, Schrader J, et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005;112:117-124.

  11. Almong Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880-885.

  12. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteremia. Intensive Care Med 2006;32:75-79.

  13. Pirat A, Zeyneloglu P, Aldemir D, Yücel M, Özen O, Candan S, et al. Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. Anesth Analg 2006;102:225-232.

  14. Fessler MB, Young SK, Jeyaseelan S, Lieber JG, Arndt PG, Nick JA, et al. A role for hydroxy-methylglutaryl coenzyme A reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 2005;171:606-615.

  15. Haidari M, Ali M, Casscells SW, Madjid M. Statins block influenza infection by down-regulating Rho/rho kinase. Circulation 2007;116:7.

  16. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005;6:82-86.

  17. Mancini GB, Etminan M, Zhang B. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-2556.

  18. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007;27:325-332.

  19. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-1012.

  20. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: a population based prospective cohort study. BMJ 2006;333:999-1004.

  21. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of antiinfluenza molecules targeting viral hemagglutinins at post-translational level. J Biol Chem 2009 Jul 28. Available at: http://www.jbc.org/cgi/reprint/M109.029470v1

  22. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it done? Lancet Infect Dis 2008;8:571-576.

  23. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006;43:199-205.

  24. Oshitani H, Kamigaki T, Suzuki A. Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2008;14:875-880.




2020     |     www.medigraphic.com